Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma

Bioanalysis

Volumn 6, Issue 2, 2014, Pages 151-164

  Bosilkovska, Marija ^a   Déglon, Julien ^b   Samer, Caroline ^a   Walder, Bernhard ^a   Desmeules, Jules ^a   Staub, Christian ^b   Daali, Youssef ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; FEXOFENADINE; FLURBIPROFEN; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; OMEPRAZOLE;

ARTICLE; CONCENTRATION (PARAMETERS); DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; ENZYME SUBSTRATE; HUMAN; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PLASMA; PROTEIN ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY;

ANIMALS; BUPROPION; CAFFEINE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DRIED BLOOD SPOT TESTING; FLURBIPROFEN; HALF-LIFE; MALE; MIDAZOLAM; OMEPRAZOLE; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY; TERFENADINE;

EID: 84892698531     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.289     Document Type: Article

References (31)

1. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin. Pharmacol. Ther. 81(2), 270-283 (2007).
2. Daali Y, Samer C, Deglon J et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin. Pharmacol. Ther. 91(3), 489-496 (2012).
3. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br. J. Clin. Pharmacol. 63(4), 477-487 (2007).
4. Ryu JY, Song IS, Sunwoo YE et al. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther. 82(5), 531-540 (2007).
5. Videau O, Delaforge M, Levi M et al. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun. Mass Spectrom. 24(16), 2407-2419 (2010).
6. Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur. J. Clin. Pharmacol. 65(6), 609-614 (2009).
7. Croft M, Keely B, Morris I, Tann L, Lappin G. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin. Pharmacokinet. 51(4), 237-246 (2012).
8. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther. 62(4), 365-376 (1997).
9. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab. Dispos. 33(12), 1859-1866 (2005).
10. Mcdade TW, Williams S, Snodgrass JJ. What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography 44(4), 899-925 (2007).
11. Deglon J, Thomas A, Mangin P, Staub C. Direct analysis of dried blood spots coupled with mass spectrometry: concepts and biomedical applications. Anal. Bioanal. Chem. 402(8), 2485-2498 (2012).
12. Ancrenaz V, Deglon J, Samer C et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 112(2), 132-137 (2013).
13. Li Y, Henion J, Abbott R, Wang P. Dried blood spots as a sampling technique for the quantitative determination of guanfacine in clinical studies. Bioanalysis 3(22), 2501-2514 (2011).
14. Filippi L, La Marca G, Cavallaro G et al. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. Epilepsia 52(4), 794-801 (2011).
15. Deglon J, Lauer E, Thomas A, Mangin P, Staub C. Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. Anal. Bioanal. Chem. 396(7), 2523-2532 (2010).
16. Barfield M, Spooner N, Lad R, Parry S, Fowles S. Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 870(1), 32-37 (2008).
17. Ansari M, Uppugunduri CR, Deglon J et al. A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 26(12), 1437-1446 (2012).
18. Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof of concept study. Antivir. Ther. 18(6), 821-825 (2013).
19. Vu DH, Bolhuis MS, Koster RA et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56(11), 5758-5763 (2012).
20. Wilhelm AJ, Klijn A, Den Burger JC et al. Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling. Ther. Drug Monit. 35(1), 92-95 (2013).
21. Deglon J, Thomas A, Daali Y et al. Automated system for on-line desorption of dried blood spots applied to LC-MS/MS pharmacokinetic study of flurbiprofen and its metabolite. J. Pharm. Biomed. Anal. 54(2), 359-367 (2011).
22. De Boer T, Wieling J, Meulman E et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed. Chromatogr. 25(10), 1112-1123 (2011).
23. Lad R. Validation of individual quantitative methods for determination of cytochrome P450 probe substrates in human dried blood spots with HPLC-MS/MS. Bioanalysis 2(11), 1849-1861 (2010).
24. Lauer E, Widmer C, Versace F et al. Body fluid and tissue analysis using filter paper sampling support prior to LC-MS/MS: application to fatal overdose with colchicine. Drug Test. Anal. (2013).
25. Heinig K, Wirz T, Bucheli F, Gajate-Perez A. Determination of oseltamivir (Tamiflu(R)) and oseltamivir carboxylate in dried blood spots using offline or online extraction. Bioanalysis 3(4), 421-437 (2011).
26. Ooms JA, Knegt L, Koster EH. Exploration of a new concept for automated dried blood spot analysis using flow-through desorption and online SPE-MS/MS. Bioanalysis 3(20), 2311-2320 (2011).
27. Deglon J, Versace F, Lauer E et al. Rapid LC-MS/MS quantification of the major benzodiazepines and their metabolites on dried blood spots using a simple and cost-effective sample pretreatment. Bioanalysis 4(11), 1337-1350 (2012).
28. Youhnovski N, Bergeron A, Furtado M, Garofolo F. Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Commun. Mass Spectrom. 25(19), 2951-2958 (2011).
29. Chainuvati S, Nafziger AN, Leeder JS et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther. 74(5), 437-447 (2003).
30. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin. Pharmacol. Ther. 80(3), 257-263 (2006).
31. Emmons G, Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2(11), 1791-1796 (2010).